Baidu
map

J Urol:局部前列腺癌高强度聚焦超声部分腺体消融的肿瘤和功能结果研究

2019-01-03 AlexYang MedSci原创

最近,有研究人员回顾性的评估了高强度超声作为局部前列腺癌起始治疗手段的结果情况。研究人员进行了一个回顾性的多中心患者分析,这些患者在2013年1月和2017年9月之间经历了部分腺体切除研究总共包括了150名患者的166次手术。其中,89%的案例表现出等级2或者更高情况。跟踪调查的平均值为24.3 ± 14.4个月。前列腺特异性抗原均值从 7.9 ± 6.8 ng/ml下降到最低值2.7 ± 3.1

最近,有研究人员回顾性的评估了高强度超声作为局部前列腺癌起始治疗手段的结果情况。研究人员进行了一个回顾性的多中心患者分析,这些患者在2013年1月和2017年9月之间经历了部分腺体切除

研究总共包括了150名患者的166次手术。其中,89%的案例表现出等级2或者更高情况。跟踪调查的平均值为24.3 ± 14.4个月。前列腺特异性抗原均值从 7.9 ± 6.8 ng/ml下降到最低值2.7 ± 3.1 ng/ml,降幅比例大65%。研究人员还在87名高风险复发的患者(52%)中进行了确定性生物活检。结果表明临床显著性癌症的检出率达42%(37个案例)。另外,那些具有更多阳性病灶的、内侧肿瘤位置或者更高前列腺特异性抗原的患者具有更高的复发可能性。研究还发现在37名患者(24.6%)中进行了挽救治疗,包括了16次重复的部分腺体切除手术。

最后,研究人员指出高强度超声部分腺体切除是安全的,并且对功能结果影响较小。局部复发和/或者治疗失败在42%的高风险复发患者中发生。内侧瘤与更高的失败率相关。严重的并发症罕见,并且81%的患者避免了全部腺体切除治疗。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046242, encodeId=3fcb20462423e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Fri Feb 08 12:26:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055075, encodeId=bd3c20550e55a, content=<a href='/topic/show?id=6b148082247' target=_blank style='color:#2F92EE;'>#聚焦超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80822, encryptionId=6b148082247, topicName=聚焦超声)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Tue Oct 29 12:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405885, encodeId=328c140588544, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421758, encodeId=d5c81421e5805, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604027, encodeId=e4ed160402ee6, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046242, encodeId=3fcb20462423e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Fri Feb 08 12:26:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055075, encodeId=bd3c20550e55a, content=<a href='/topic/show?id=6b148082247' target=_blank style='color:#2F92EE;'>#聚焦超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80822, encryptionId=6b148082247, topicName=聚焦超声)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Tue Oct 29 12:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405885, encodeId=328c140588544, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421758, encodeId=d5c81421e5805, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604027, encodeId=e4ed160402ee6, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046242, encodeId=3fcb20462423e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Fri Feb 08 12:26:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055075, encodeId=bd3c20550e55a, content=<a href='/topic/show?id=6b148082247' target=_blank style='color:#2F92EE;'>#聚焦超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80822, encryptionId=6b148082247, topicName=聚焦超声)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Tue Oct 29 12:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405885, encodeId=328c140588544, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421758, encodeId=d5c81421e5805, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604027, encodeId=e4ed160402ee6, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-01-05 chg122
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046242, encodeId=3fcb20462423e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Fri Feb 08 12:26:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055075, encodeId=bd3c20550e55a, content=<a href='/topic/show?id=6b148082247' target=_blank style='color:#2F92EE;'>#聚焦超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80822, encryptionId=6b148082247, topicName=聚焦超声)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Tue Oct 29 12:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405885, encodeId=328c140588544, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421758, encodeId=d5c81421e5805, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604027, encodeId=e4ed160402ee6, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046242, encodeId=3fcb20462423e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Fri Feb 08 12:26:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055075, encodeId=bd3c20550e55a, content=<a href='/topic/show?id=6b148082247' target=_blank style='color:#2F92EE;'>#聚焦超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80822, encryptionId=6b148082247, topicName=聚焦超声)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Tue Oct 29 12:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405885, encodeId=328c140588544, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421758, encodeId=d5c81421e5805, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604027, encodeId=e4ed160402ee6, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 05 05:26:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-01-05 aids219

相关资讯

Nutrients:膳食锌和前列腺癌风险研究

锌是正常前列腺代谢的一种关键微量元素,在恶性肿瘤细胞中减少。然而,膳食锌与前列腺癌(PCa)之间的相关性在流行病学中仍旧是有争议的。最近,有研究人员在一个西班牙案例对照研究MCC研究中探索了上述关系,并考虑了肿瘤恶化和扩展情况,以及PC遗传敏感位点。研究总共包括了733名案例和1228名对照。研究人员使用一个食物频率调查问卷来评估膳食锌,并利用基于单核苷酸多态性的多基因分线评分(PRS)对遗传敏感

Oncogene:雄激素信号对起始于前列腺基层细胞的前列腺癌的发展是必需的

越来越多的证据表明前列腺基层细胞和腔细胞均能够起始致癌性转化。然而,尽管肿瘤起始细胞具有多态性,大多数前列腺癌细胞表达雄激素受体(AR)并且依赖于雄激素进行生长和扩张,表明了雄激素信号在前列腺致癌过程中的必要角色。前列腺基底细胞能够表达p63并且能够分化成为腔内、神经内分泌和基底细胞。最近,有研究人员直接评估了雄激素信号在前列腺p63表达细胞起始的致癌性转化和肿瘤形成中的必要角色。研究人员使用了新

J Urol:局部高等级前列腺癌的初步治疗中,手术治疗和放射治疗癌症特异性死亡率评估

年龄稍小男性中局部高等级前列腺癌的最优初始治疗手段仍旧是有争议的。最近,有研究人员比较了起始根治性前列腺切除和放射治疗对小于60岁男性生存结果的影响。研究包括了2228名男性,其中1459名(65.5%)经历了起始手术治疗,平均跟踪调查的时间为43个月,769名(34.5%)男性经历了体外放射治疗,带有或者不带有近距离放射治疗,平均跟踪调查的时间为44个月。在多变量分析中,在控制了年龄、生物活检格

PNAS:在去势难治性前列腺癌中,以雄激素受体信号为靶标的脂肪生成从头抑制研究

前列腺癌恶化的一个标志是通过脂肪酸合成酶(FASN)过表达而引起的脂肪代谢的异常调控。FASN是脂肪酸从头合成的一个关键酶。转移去势难治性前列腺癌(mCRPC)可以通过很多种机制发展为雄激素受体(AR)信号抑制剂的抗性情况,包括了AR变异体V7(AR-V7)的持续性激活。最近,有研究人员开发了一种FASN抑制剂(IPI-9119),并且阐释了选择性的FASN抑制剂能够通过代谢重组拮抗CRPC生长,

XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果

安斯泰来制药公司和辉瑞公司近日宣布,在评估XTANDI(恩杂鲁胺)的III期ARCHES试验中,与单独使用雄激素剥夺疗法(ADT)相比,XTANDI联合ADT在转移性激素敏感性前列腺癌(mHSPC)男性患者的治疗中达到了其主要终点,显著改善了患者的无进展生存期(rPFS)。

盘点:前列腺治疗方法进展

【1】Eur J Cancer Care (Engl):接受新药物治疗的前列腺癌患者的疲劳、治疗满意度和健康相关生活质量研究 临床研究已经阐释了醋酸阿比特龙+强的松(AAP)和恩杂鲁胺(ENZ)在显著改善转移性去势难治性前列腺癌患(mCRPC)者生存中的作用。然而,考虑到患者现实生活中的经历,尤其是考虑到疲劳、治疗满意度和健康生活质量(HRQoL),相关的研究很有限。最近,有研究人员

Baidu
map
Baidu
map
Baidu
map